You are here
Ewa Olech MD
Seminars in Arthritis and Rheumatism: Volume 45, Issue 5, Supplement, April 2016, Pages S1-S10
Safety, Efficacy, and Pharmacokinetic Bioequivalence of Biosimilar Tumor Necrosis Factor-Alpha Inhibitors Compared with Their Reference Biologics: A Systematic Review
Chingcuanco F, Segal J, Kim SC, Alexander GC
Value in Health, Volume 19, Issue 3, May 2016, Page A226Topic: Safety
Luca Pasina, Gianluigi Casadei, Alessandro Nobili
European Journal of Internal Medicine, Volume 33, September 2016, Pages 28 - 35
Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data
Elena Nikiphorou, Hannu Kautiainen, Pekka Hannonen, Juha Asikainen, Arto Kokko, Tuomas Rannio & Tuulikki Sokka pages 1677-1683Expert Opinion on Biological Therapy, Volume 15, Issue 12, 2015
Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
Woodworth TG, den Broeder AA.Best Practice & Research Clinical Rheumatology, Volume 29, Issues 4–5, August–December 2015, Pages 543–549
Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health
Braun J, Kudrin A.Biologicals, Available online 23 April 2016, In Press, Corrected Proof
This month the article: Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public...
Dörner T, Kay JNature Reviews Rheumatology 2015 Dec;11(12):713-24. doi: 10.1038/nrrheum.2015.110. Epub 2015 Aug 18.
Choy E, Jacobs IASeminars in Oncology. 2014 Feb; 41 Suppl 1:S3-14. doi: 10.1053/j.seminoncol.2013.12.001. Epub 2013 Dec 6.